Smad3 promotes adverse cardiovascular remodeling and dysfunction in doxorubicin-treated hearts.
Cobb MS, Tao S, Shortt K, Girgis M, Hauptman J, Schriewer J, Chin Z, Dorfman E, Campbell K, Heruth DP, Shohet RV, Dawn B, Konorev EA. Smad3 promotes adverse cardiovascular remodeling and dysfunction in doxorubicin-treated hearts. Am J Physiol Heart Circ Physiol. 2022 12 01; 323(6):H1091-H1107.